Abstract: A method of making an antimicrobial poly(methyl methacrylate) (PMMA)/silver nanocomposite comprising PMMA and silver nanoparticles. The method includes reacting at least one silver salt with a methyl methacrylate (MMA) monomer in at least one organic solvent free of water and in the presence of at least one organic free radical initiator to polymerize the MMA monomer to form the PMMA by free radical polymerization while reducing in-situ the silver salt to form the silver nanoparticles, wherein the silver nanoparticles have an average particle size of 35-60 nm, and wherein the PMMA forms a matrix that encloses the silver nanoparticles.
Type:
Grant
Filed:
July 12, 2019
Date of Patent:
October 25, 2022
Assignee:
KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS
Inventors:
Mohammad Nahid Siddiqui, Dimitris S. Achilias, Halim Hamid Redhwi
Abstract: An anhydrous and alcohol-free slow fragrance diffusive composition (lotion, gel or cream) with longer lasting properties than hydroalcoholic formula fragrance product that contains 50 to 75 percent by weight dimethicone crosspolymer gel, 0.01 to 30 percent by weight fragrance oil and 5 to 40 percent by weight volatile linear silicone fluid. Emollients may be added to moisturize the skin, improve the fragrance rendition and/or increase the miscibility of the fragrance oil in the composition when a high level of dimethicone is used (in case of a lotion for example). Moreover, a preservative and some pigments can be added to the formula to preserve the fragrant product from bacteria contamination and to improve the aesthetics respectively.
Abstract: The present invention provides a composition comprising (A) a compound of formula (I): wherein R1 is methyl or methoxy, R2 is hydrogen, methyl or ethoxy and A is a substituted heteroaryl group, or an N-oxide or salt form thereof, and (B) one or more further herbicides; as well as the use of such compositions in controlling plants or inhibiting plant growth.
Type:
Grant
Filed:
February 5, 2020
Date of Patent:
October 18, 2022
Assignee:
SYNGENTA CROP PROTECTION AG
Inventors:
Sally Elizabeth Russell, Sean Ng, James Alan Morris
Abstract: A method of production of a tissue sealing patch is disclosed. The method comprises casting a polymer film from a biocompatible polyethylene glycol-caprolactone-lactide triblock copolymer (PECALA); softening the polymer film; placing a powdered tissue sealant material on a surface of said polymer film; and, pressing said polymer film to at least partially incorporate the sealant material into said surface of said polymer film. In some embodiments of the invention, the polymer film is created by heating and evacuating a work surface; applying a solution of PECALA to said work surface; adjusting a polymer blade to a predetermined height above said work surface; spreading said solution of PECALA over said work surface with said polymer blade; and evaporating said solvent. The PECALA preferably comprises PEG-CL-LA units connected by urethane linkages, PEG having a molecular weight of between 3000 and 3500 amu, and a CL:LA:PEG ratio of 34:2:1.
Abstract: The present invention relates generally to compositions and methods comprising abiotic, synthetic polymers with affinity and specificity to proteins. The synthetic polymers are an improvement over biological agents by providing a simpler, less expensive, and customizable platform for binding to proteins. In one embodiment, the compositions and methods relate to synthetic polymers with affinity and specificity to vascular endothelial growth factor (VEGF). In one embodiment, the compositions are useful for treating diseases and disorders related to the overexpression of VEGF. In one embodiment, the compositions are useful for treating cancer. In one embodiment, the compositions are useful for detecting VEGF levels from biological samples. In one embodiment, the compositions are useful for detecting overexpression of VEGF from biological samples. In one embodiment, the compositions are used to diagnose cancer.
Type:
Grant
Filed:
August 25, 2017
Date of Patent:
October 4, 2022
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: Provided herein are a biofilm inhibiting composition, a biofilm inhibiting article, and a method of reducing planktonic growth or biofilm formation. The biofilm inhibiting composition includes a fluid and at least one biofilm inhibiting compound selected from the group consisting of acetoacetate (AAA) and ethyl acetoacetate (EAA). The biofilm inhibiting article includes a substrate and at least one biofilm inhibiting compound selected from the group consisting of acetoacetate (AAA) and ethyl acetoacetate (EAA). The method of reducing biofilm formation includes providing a biofilm inhibiting compound selected from the group consisting of acetoacetate (AAA) and ethyl acetoacetate (EAA), and contacting an article with the biofilm inhibiting compound.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
September 27, 2022
Assignee:
NDSU RESEARCH FOUNDATION
Inventors:
Birgit M. Prüß, Meredith Schroeder, Shelley M. Horne, Shane J. Stafslien
Abstract: The present invention includes pourable, non-toxic lubricating compositions containing carrageenan and more precisely ? carrageenan as an anti-viral agent, for protection from Human Papillomavirus (HPV), and methods of using the lubricating compositions as a non-oily, psuedoplastic lubrication product and administering the carrageenan for reducing the propagation of HPV during sexual activity.
Abstract: The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.
Type:
Grant
Filed:
January 21, 2021
Date of Patent:
September 13, 2022
Assignee:
Axsome Malta Ltd.
Inventors:
Clark Patrick Allphin, Edwin Gerard Walsh
Abstract: A construct includes a core comprising an external surface and a plurality of pores, a cargo disposed in a pore of the plurality of pores, the cargo comprising a CRISPR Cas9 component or a nucleic acid sequence encoding a CRISPR Cas9 component; and a coating coupled to the core, wherein the coating comprises a cationic lipid, a pegylated lipid, a zwitterionic lipid, and a sterol. The coating may comprise a molar ratio of about 1 cationic lipid to 1 zwitterionic lipid to 0.9 sterol to 0.15 PEGylated lipid, wherein each molar ratio optionally varies by about plus or minus 10%. A method of treatment is also provided.
Type:
Grant
Filed:
April 3, 2020
Date of Patent:
September 6, 2022
Assignee:
National Technology & Engineering Solutions of Sandia, LLC
Inventors:
Oscar Negrete, Annette Estelle LaBauve, Joseph S. Schoeniger, Edwin A. Saada
Abstract: The present disclosure relates to methods and devices to improve respiratory system health, increase resistance to infection, and increase the hypothiocyanate ion in mammalian lungs. The methods generally comprise: generating a Hydrogen Peroxide Gas that is non-hydrated and free of ozone, and directing the gas comprising primarily Hydrogen Peroxide Gas into an environment and exposing a subject to the environment such that the Hydrogen Peroxide Gas acts to the increase of the hypothiocyanate ion in mammalian lungs.
Abstract: The present invention relates to a drug delivery system, in particular for a controlled administration of one or more active pharmaceutical ingredients to a body, and further in particular for oral administration of one or more active pharmaceutical ingredients to a body. The system thereby comprises a base component soluble in body fluids and a separate first component soluble in body fluids. The first component thereby comprises a therapeutically effective amount of a first active pharmaceutical ingredient.
Type:
Grant
Filed:
December 29, 2017
Date of Patent:
August 23, 2022
Assignees:
Laxxon Medical AG, Exentis Knowledge GmbH
Inventors:
Achim Schneeberger, Klaus Kühne, Helmut Kerschbaumer, Srdan Vasic
Abstract: The invention relates to a composition and a method of darkening human skin. The composition comprises select alkyl or alkyloxy benzoic acids.
Abstract: A hydrogel particle that has an average cross-sectional diameter in the range from 1 micrometer (?m) to 1000 ?m, wherein the particle includes a first polymer network with an average mesh size that allows diffusion of a molecule with an hydrodynamic radius of 1000 nanometer (nm) or less into the first polymer network and which particle includes one or more binding molecules that are immobilized by the polymer network. The hydrogel particle preferably has wherein the first polymer network has an average mesh size that prevents diffusion of a molecule with an average hydrodynamic radius of more than 1000 nm to diffuse into the first polymer network, preferably the mesh size prevents diffusion of a molecule with an average hydrodynamic radius of more than 100 nm, and preferably more than 5 nm. Methods for reducing the bioavailability of one or more soluble biological molecules in a biological system by using the described hydrogel particle.
Type:
Grant
Filed:
January 18, 2019
Date of Patent:
August 16, 2022
Assignee:
HY2CARE B.V.
Inventors:
Tom Kamperman, Lisanne Paula Karbaat, Hermanus Bernadus Johannes Karperien, Jeroen Christianus Hermanus Leijten, Pieter Jelle Dijkstra, Bram Zoetebier
Abstract: The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
August 9, 2022
Assignee:
Unicycive Therapeutics, Inc.
Inventors:
Ashok Yeshwant Gore, Milind Dixit, Ravichandran Mahalingam, Edward A. Schauer, Matthew Stewart, Rajendra Tandale, Ramsharan Singh
Abstract: According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
Type:
Grant
Filed:
March 27, 2020
Date of Patent:
June 7, 2022
Assignee:
TherapeuticsMD, Inc.
Inventors:
Brian A. Bernick, Thorsteinn Thorsteinsson, Peter H. R. Persicaner, Janice Louise Cacace, Frederick D. Sancilio, Neda Irani, Julia Amadio
Abstract: A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.
Type:
Grant
Filed:
March 8, 2019
Date of Patent:
May 24, 2022
Assignees:
WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., WUHAN QR PHARMACEUTICALS CO., LTD., WUHAN ZY PHARMACEUTICALS CO., LTD.
Abstract: The present disclosure relates gold carbene naphthoquinone compounds and salts thereof. In some aspects, these compounds can be used to treat cancer including cancers which are resistant to one or more other chemotherapeutic agents such as cisplatin or platinum chemotherapeutic agents. Also provided herein are pharmaceutical compositions comprising the gold carbene naphthoquinone compounds.
Type:
Grant
Filed:
June 29, 2018
Date of Patent:
May 17, 2022
Assignees:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, GEORGIA SOUTHERN UNIVERSITY, WRIGHT STATE UNIVERSITY
Inventors:
Jonathan Arambula, Kuppuswamy Arumugam, Jonathan L. Sessler, Christopher Bielawski
Abstract: The present invention relates to the field of carrier and delivery systems for active molecular compounds. In particular, the present invention provides aqueous dispersions for delivery of active molecular compounds.
Abstract: In one embodiment, the present invention provides a composition, wherein the composition is a porous scaffold, wherein the pores of the scaffold are from 1 to 500 microns, the composition comprising: a) a cross-linkable protein selected from the group consisting of collagen and gelatin; b) a cross-linker which induces cross-linking of the cross-linkable protein; and c) a liquid.